From the pathophysiology and prevention of the ovarian hyperstimulation syndrome (OHSS) to therapy strategies - An overview;Von der pathophysiologie und prävention des ovariellen überstimulationssyndroms (OHSS) bis zur stadiengerechten therapie

Geburtshilfe und Frauenheilkunde

Volumn 62, Issue 12, 2002, Pages 1155-1161

  Kissler, Stefan ^a   Siebzehnrubl E ^a   Kaufmann, M ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

Capillary permeability; Cytokines; OHSS; Prevention; Therapy

Indexed keywords

CHORIONIC GONADOTROPIN; CYTOKINE; HUMAN MENOPAUSAL GONADOTROPIN; INTERLEUKIN 1; INTERLEUKIN 2; INTERLEUKIN 6; INTERLEUKIN 8; RECOMBINANT FOLLITROPIN; TUMOR NECROSIS FACTOR ALPHA; VASCULOTROPIN;

ANGIOGENESIS; ASCITES; CAPILLARY PERMEABILITY; FLUID SHIFT; HUMAN; INFERTILITY THERAPY; OVARY CYCLE; OVARY DISEASE; OVULATION INDUCTION; PATHOPHYSIOLOGY; PLEURA EFFUSION; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; TROPHOBLAST;

EID: 0036942941     PISSN: 00165751     EISSN: None     Source Type: Journal    
DOI: 10.1055/s-2002-36363     Document Type: Review

References (53)

1. Aboulghar M, Evers JH, Al-Inany H. Intra-venous albumin for preventing severe ovarian hyperstimulation syndrome. Cochrane Database Syst Rev 2000; 2: CD001302
2. Abramov Y, Schenker JG, Lewin A et al. Plasma inflammatory cytokines correlate to the ovarian hyperstimulation syndrome. Hum Reprod 1996; 11: 1381-1386
3. Abramov Y, Barak V, Nisman B, Schenker JG. Vascular endothelial growth factor plasma levels correlate to the clinical picture in severe ovarian hyperstimulation syndrome. Fertil Steril 1997; 67: 261-265
4. al-Shawaf T, Zosmer A, Hussain A, Tozer A, Panay N, Wilson C, Lower AM, Grudzinskas JG. Prevention of severe ovarian hyperstimulation syndrome in IVF with or without ICSI and embryo transfer: a modified "coasting" strategy based on ultrasound for identification of high-risk patients. Hum Reprod 2001; 16: 24-30
5. Araujo E, Bernardini L, Frederick JL. Prospective randomized comparison of human chorionic gonadotrophin versus intramuscular progesterone for luteal-phase support in assisted reproduction. J Assist Reprod Genet 1994; 11: 74-78
6. Blumenfeld Z, Lang N, Amit A et al. Native gonadotropin-releasing hormone for triggering follicular maturation in polycystic ovary syndrome patients undergoing human menopausal gonadotropin ovulation induction. Fertil Steril 1994; 62: 456-460
7. Chen CD, Wu MY, Yang JH et al. Intravenous albumin does not prevent the development of severe ovarian hyperstimulation syndrome. Fertil Steril 1998; 68: 287-291
8. Claman P, Domingo M, Leader A et al. Luteal-phase support in an invitro fertilization program using gonadotropin-releasing hormone analogue (GnRHa) before superovulation. Hum Reprod 1992; 7: 487-491
9. Der-Chen C, Fu-Chen H, Fen-Lu H et al. Value of serum and follicular fluid cytokine profile in the prediction of moderate to severe ovarian hyperstimulation syndrome. Hum Reprod 2000; 15: 1037-1042
10. Egbase PE, Al-Sharhan M, Grudzinskas JG. Early unilateral follicular aspiration compared to coasting for the prevention of severe ovarian hyperstimulation syndrome: a prospective randomized study. Hum Reprod 1999; 14: 1421-1425
11. Egbase PE, Makhseed M, Al Sharhan M, Grudzinskas JG. Timed unilateral ovarian follicular aspiration prior to administration of human chorionic gonadotropin for the prevention of severe ovarian hyperstimulation syndrome in in-vitro-fertilization: a prospective randomised study. Hum Reprod 1997, 12: 2603-2606
12. Egbase PE, Al-Sharhan M, Berlingieri P, Grudzinskas JG. Serum oestradiol and progesterone concentrations during prolonged coasting in 15 women at risk of ovarian hyperstimulation syndrome following ovarian stimulation for assisted reproduction treatment. Hum Reprod 2000; 15: 2082-2086
13. Elchalal U, Schenker JG. The pathophysiology of ovarian hyperstimulation syndrome - views and ideas. Hum Reprod 1997; 12: 1129-1137
14. Gerris J, De-Vits A, Joostens M, Van-Royen E. Triggering of ovulation-induction in human menopausal gonadotropin-stimulated cycles: comparison between intravenously administered gonadotropin-releasing hormone (100 and 500 micrograms), GnRH agonist (buserelin, 500 micrograms) and human chorionic gonadotropin (10,000 IU). Hum Reprod 1995; 10: 56-62
15. Felberbaum R, Reissmann T, Küpker W, Diedrich K. Preserved pituitary response under ovarian stimulation with HMG and GnRH antagonist (Cetrorelix) in women with tubal infertility. Eur J Obstet Gynecol Reprod Biol 1995; 61: 151-155
16. Ferraretti AP, Gianaroli L, Magli C, Fortini D, Selman HA, Feliciani E. Elective cryopreservation of all pronucleate embryos in woman at risk of ovarian hyperstimulation syndrome: efficiency and safety. Hum Reprod 1999; 14: 1457-1460
17. Golan A, Ron-El R, Herman A, Soffer Y, Weinraub Z, Capsi E. Ovarian hyperstimulation syndrome: an update review. Obstet Gynecol 1989; 44: 430-440
18. Hack CE, DeGroot ER, Felt-Bersma RJF. Increased plasma levels of interleukin-6 in sepsis. Blood 1989; 74: 1704-1710
19. Haning RV, Srawn EY, Nolten WE. Pathophysiology of the ovarian hyperstimulation syndrome. Obstet Gynecol 1985; 66: 882-889
20. Jäger W, Wildt L, Lang N. Ovarian hyperstimulation syndrome. In: Hafez ESE (Ed). Assisted Human Reproductive Technology. 1991: 61-75
21. Kodama H, Fukuda J, Karube H, Matsui T, Shimizu Y, Tanaka T. Characteristic of blood hemostatic markers in a patient of ovarian hyperstimulation syndrome who actually developed thromboembolism. Fertil Steril 1995; 64: 1207-1209
22. Keck C, Neulen J, Breckwoldt M. Das ovarielle Hyperstimulationssyndrom. Geburtsh Frauenheilk 1994; 54: 315-320
23. Kissler S, Neidhardt B, Siebzehnruebl E, Schmitt H, Tschaikowsky K, Wildt L. The detrimental role of colloidal volume substitutes in severe ovarian hyperstimulation sydrome - a case report. Eur J Obstet Gynecol 2001; 99: 131-134
24. Knox GE. Antihistamine blockade of the ovarian hyperstimulation syndrome. Am J Obstet Gynecol 1974; 118: 992-994
25. Krasnow JS, Berga SL, Gusick DS et al. Vascular permeability factor and vascular endothelial growth factor in ovarian hyperstimulation syndrome - a preliminary report. Fertil Steril 1996; 65: 552-555
26. Lewit N, Kol S, Manor D, Itskovitz-Eldor J. Comparison of GnRH-analogues and HCG for the induction of ovulation and prevention of ovarian hyperstimulation syndrome: a case control-study. Hum Reprod 1996; 11: 1399-1402
27. Ludwig M, Diedrich K. Evaluation of an optimal luteal phase support protocol in IVF. Acta Obstet Gynaecol Scand 2001; 80: in press
28. Ludwig M, Felberbaum RE, Devroey P, Albano C, Riethmüller-Winzen H, Schüler A, Engel J, Diedrich K. Significant reduction of the incidence of ovarian hyperstimulation syndrome (OHSS) by using the LHRH antagonist Cetrorelix in controlled ovarian stimulation for assisted reproduction. Arch Gynecol Obstet 2000; 264: 29-32
29. Ludwig M, Finas A, Katalinic A, Strik D, Kowalcek I, Schwartz P, Felberbaum R, Kupker W, Schopper B, Al-Hasani S, Diedrich K. Prospective, randomized study to evaluate the success rates using HCG, vaginal progesterone or a combination of both for luteal support. Acta Obstet Gynaecol Scand 2001; 80: 574-582
30. Ludwig M, Bauer O, Lopens A, Jelkmann W, Diedrich K. Serum concentration of vascular endothelial growth factor cannot predict the course of severe ovarian hyperstimulation syndrome. Hum Reprod 1998; 13: 30-32
31. Meirow D, Schenker JG, Rosler A. Ovarian hyperstimulation syndrome with low oestradiol in non-classic 17alpha-hydroxylase, 17, 20-lyase deficiency: What is the role of oestrogens? Hum Reprod 1996; 11: 2119-2121
32. Morris RS, Wong IL, Kirkman E et al. Inhibition of ovarian-derived prorenin to angiotensin cascade in the treatment of ovarian hyperstimulation syndrome. Hum Reprod 1995; 10: 1355-1358
33. Mozes M, Bogokowsky H, Antebi E, Lunenfeld B, Rabau E, Serr DM et al. Thromboembolic phenomena after ovarian stimulation with human gonadotrophins. Lancet 1965; 2: 1213-1215
34. Navot D, Margalioth EJ, Laufer N. Direct correlation between plasma renin activity and severity of ovarian hyperstimulation syndrome. Fertil Steril 1987; 48: 57-61
35. Neulen J, Yan Z, Raczek S et al. Human chorionic gonadotropin-dependant expression of vascular endothelial growth factor/vascular permeability factor in human granulosa cells: importance in ovarian hyperstimulation syndrome. J Clin Endocrinol Metabol 1995; 80: 1967-1971
36. Neulen J. Das ovarielle Überstimulationssyndrom. Geburtsh Frauenheilk 2001; 61: XLI-XLIII
37. Neulen J. Reproduktionsmedizin. In: Keck C, Neulen J, Breckwoldt M (Hrsg). Endokrinologie, Reproduktionsmedizin, Andrologie. 1. Aufl. Stuttgart: Thieme, 1997: 132-135
38. Okusawa S, Gelfand J, Alkefima T et al. Interleukin 1 induces a shock-like state in rabbits: Synergism with tumor necrosis factor and the effect of cyclooxygenase inhibition. J Clin Invest 1988; 81: 1162-1172
39. Olivennes F. Induction of final oocyte maturation by a single dose of GnRH agonist after Ganirelix treatment. Gynecol Endocrinol 2001; 15 (Suppl 1): 7
40. Olivennes F, Fanchin R, Bouchard P, Taieb J, Frydman R. Triggering of ovulation by a gonadotrophin-releasing hormone (GnRH) agonist in patients pretreated with a GnRH-antagonist. Fertil Steril 1996; 66: 151-153
41. Quenaan JTJ, Veeck LL, Toner JP, Oehninger S, Muasher SJ. Cryopreservation of all prezygotes in patients at risk of severe hyperstimulation does not eliminate the syndrome, but the chances of pregnancy are excellent with subsequent frozen-thaw transfers. Hum Reprod 1997; 12: 1573-1576
42. Ravindranath N, Little-Ihrig L, Phillips HS. Vascular endothelial growth factor mRNA expression in the primate ovary in relation to follicular growth and corpus luteum function. Endocrinol 2001; 2065: 254-260
43. Rimington MR, Walker SM, Shaw RW. The use of laparoscopic ovarian electrocautery in preventing cancellation of in-vitro fertilisation treatment cycles due to risk of ovarian hyperstimulation syndrome in women with polycystic ovaries. Hum Reprod 1997; 12: 1443-1447
44. Schenker JG, Polishuk WZ. Ovarian hyperstimulation syndrome. Obstet Gynecol 1975; 46: 23-28
45. Schenker JG, Polishuk WZ. The role of prostaglandins in ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 1976; 6: 47-52
46. Schwartz M, Jewelewicz R. The use of gonadotropins for induction of ovulation. Fertil Steril 1981; 35: 3-12
47. Senger DR, Galli SJ, Dvorak AM et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219: 983-985
48. Shaker AG, Zosmer A, Dean N, Bekir JS, Jacobs HS, Tan SL. Comparison of intravenous albumin and transfer of fresh embryos with cryopreservation of all embryos for subsequent transfer in prevention of ovarian hyperstimulation syndrome. Fertil Steril 1996; 65: 992-996
49. Sher G, Zouves C, Feinman M, Maassarani G. "Prolonged coasting": an effective method for preventing severe ovarian hyperstimulation syndrome in patients undergoing in-vitro fertilisation. Hum Reprod 1995; 10: 3107-3109
50. Thaler I, Yoffe N, Kaftory JK, Brandes JM. Treatment of ovarian hyperstimulation syndrome: the physiological basis for a modified approach. Fertil Steril 1981; 36: 110-113
51. Watson JM, Sensintaffar FL, Berek JS, Martinez-Masa O. Constitutive production of IL-6 by ovarian cancer cell-lines and by primary ovarian tumor cultures. Cancer Res 1990; 50: 6959-6965
52. World Health Organization. Agents stimulating gonadal function in humans. WHO Techn Rep Series 1973: 514
53. Zaides I, Friedman M, Lindenbaum ES et al. Serotonin and the ovarian hyperstimulation syndrome. Eur J Obstet Gynecol Reprod Biol 1983; 15: 55-61